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1. Introduction 
In this review, we examine the chelating ligand design and coordination complexes of 
radioactive lanthanide isotopes. Where appropriate, discussion is placed in the context 
of the radioimaging and radiotherapeutic applications of such complexes. This, of 
course, is a very large subject area, and we have therefore selected, where possible, 
those examples that illustrate the underlying coordination chemistry features of the 
ligand systems in question, and how they are suitable for the target applications. In 
some instances, we shall refer to clinical work, both as a means of illustrating the 
translational potential of radiolanthanide coordination chemistry systems and to 
provide readers with an appreciation of the ever-expanding application areas of these 
materials.   
 The use of radioisotopes in diagnostic imaging science is currently dominated 
by a relatively small number of isotopes. These include the single gamma photon 
emitting isotopes 99mTc, 67Ga and 111In (see Table 1) that are employed in gamma 
photography techniques,1 such as 67Ga scintigraphy (a ‘gallium’ scan) and single-
photon emission computed tomography (SPECT); currently 99mTc accounts for 
approximately 80% of all nuclear medicine procedures where (99mTc-tetrofosmin for 
cardiac perfusion). In positron emission tomography (PET), β+ emission followed by 
electron annihilation results in the emission of collinear gamma rays, a method 
dominated by widely available 18F tracers (e.g. 18F-fluorodeoxyglucose is used as a 
metabolic indicator). The decay properties of a given tracer are of course of paramount 
importance in developing viable applications. For example, when considering the 
suitability of an isotope as a potential PET tracer, many factors must be examined. Of 
central importance is the β+ emission energy (not to be confused with the 511 keV 
	 3	
annihilation energy) which determines the range of the emitted positrons (mean free 
paths) in condensed matter, and hence set a limit to the resolution of PET scans. To 
illustrate this we can compare the well documented examples of 18F and 15O, which 
possess maximum emission energies of 675 and 1720 keV respectively, with the 
corresponding FWTM (full width at tenth of maximum) scatter values of 1.03 mm and 
4.14 mm.2 The lower ‘scatter’ of 18F results in considerably better spatial resolution in 
PET imaging. Whilst comparable studies are to date lacking for the radiolanthanides, 
it is reasonable to predict that β+ isotopes with energies in these energy ranges would 
yield comparable results, and clearly isotopes with lower energies would yield better 
imaging performance. 
  While the clear majority of current clinical diagnostic imaging and radiotherapy 
is dominated by a small number of isotopes (e.g. Table 1) the ever-increasing access 
to ‘new’ isotopes have expanded the medical radiochemist’s repertoire of available 
materials and modalities. To a large extent, this expansion is being driven by the 
availability of new metal isotopes and hence the development of new diagnostics, 
therapies, and the emerging science of theranostic agents, is one in which the 
coordination chemist is set to play an important role. Lanthanide radioisotopes also 
find extensive use as therapeutic agents, with a relatively small number of potential 
systems exploited in this respect.3  Here, the β-emitters dominate, with 153Sm and 
177Lu (and the group 3 element 90Y, often referred to as a pseudo lanthanide) 
commonly studied with the emission energies of these species sufficient to allow 
significant tissue penetration. In this context, Neves et al. reviewed the potential of 
unexploited radionuclides, including a number of radiolanthanides, a decade ago. 4  
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Table 1. Radioactive properties of selected isotopes commonly used in nuclear 
medicine. EC = electron capture; IT = isomeric transition. Data is drawn from reference 
[5].  
 
This review is structured to provide the reader with an overview of the different 
radiolanthanide isotopes (and their potential in an imaging and therapeutic context) as 
well as the different classes of chelating ligands that have been thus far investigated 
in the coordination chemistry of radiolanthanides. We have limited our discussion to 
examples from the literature that demonstrate the breadth of the topic, particularly in 
a coordination chemistry context, and point to future directions for this multidisciplinary 
topic. 
 
 
  
Radionuclide	 Half-life	 Decay mode(s)	 Uses	
18F	 1.83 h		 b+ (633.5 keV), EC / g (511 keV)	 Imaging	
64Cu	 12.70 h	 b-  (578 keV, 40%), b
+ (650 keV, 19%), EC (41%)	 Imaging	
67Ga	 3.26 d	 EC / g (93 keV, 37%; 184 keV, 20%; 300 keV, 17%)	 Imaging	
68Ga	 1.13 h	 b+ (830 keV, 90%), EC (10%)	 Imaging	
82Rb	 1.27 min	 b+ (3.379 keV, 96%), EC (4%) / g (511, 767 keV)	 Imaging	
90Y	 2.67 d	 b-  (2.282 MeV)	 Therapy	
99mTc	 6.01 h	 IT (142 keV)	 Imaging	
111In	 2.80 d	 EC / g (171, 245 keV)	 Imaging	
131I	 8.04 d	 b-  (0.971 MeV) / g (80, 284, 364, 637 keV)	 Therapy	
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2. Radiolanthanide isotopes 
Although there are hundreds of radiolanthanide isotopes described in the literature, 
we have chosen to focus upon those radiolanthanide species for which some form of 
descriptive coordination chemistry is available. The radiolanthanides discussed in this 
review are summarised in Table 2.   
Radionuclide Half-life Decay mode(s) 
Uses / 
Potential Uses 
134La 6.5 m b+ (63%, 2.67 MeV), EC (37%) / g 
(605 keV) 
 
140La 1.678 d b-  (3.76 MeV)  
134Ce 3.16 d	 EC (500 keV)/ g (130, 162, 605 keV) Therapy 
141Ce 32.5 d b-  (69%, 436 keV; 31%, 581 keV) Tracer 
144Ce 284.6d b-  (185, 318 keV) Tracer 
140Pr 3.39 m b+ (51%, 2.37 MeV), EC (49%) / g 
(307, 1597 keV)   
 
143Pr 13.58 d b-  (933 keV), g (742 keV) Therapy 
144Pr 17.28 m b-  (98%, 2.996 MeV)  
140Nd 3.37 d EC (220 keV) Imaging 
147Nd 10.98 d b-  (895 keV), g (531, 91 to 686 keV) Therapy 
149Pm 2.21 d b-  (1.071 MeV), g (286, 591, 859 keV) Therapy 
153Sm 1.929 d b-  (808 keV) Therapy (bone) 
149Gd 9.2 d EC (1.32 MeV), g (150, 296, 347 keV)  
149Tb 4.13 h a (16%, 3.97 MeV), b+ (4%, 1.8 MeV)  
152Tb 17.5 d EC (80%, 2.8 MeV), b+ (20%, 2.5 
MeV) 
Imaging 
155Tb 5.3 d EC (0.82 MeV), g (87, 105 keV) Imaging 
161Tb 6.91 d b-  (593 keV), g (26, 49, 75 keV) Therapy 
157Dy 8.1 h  EC (1.34 MeV) Imaging 
165Dy 2.33 h b-  (1.286 MeV), g (95 keV) Therapy 
166Dy 3.40 d b-  (486 keV), g (28, 83 keV) Therapy 
161Ho 2.48 h EC (859 keV) Imaging	
166Ho 1.12 d b-  (51%, 1.855 MeV; 49% 1.776 
MeV), g (83 keV, 1.38 MeV) 
Therapy 
160Er 1.191 d EC (330 keV) Imaging	
165Er 10.36 h EC  (376 keV) Therapy 
169Er 9.4 d b-  (350 keV), g (111, 112 keV)  
171Er 0.31 d b-  (1.49 MeV), g (111, 296, 308 keV)  
167Tm 9.24 d EC (748 keV)  
170Tm 128.6 d b-  (99.8 %, 883, 968 keV) Therapy 
166Yb 2.36 d EC (300 keV)  
175Yb 4.19 d b-  (73%, 466 keV; 21%, 71 keV; 6%, 
353 keV), g (114, 396 keV) 
Therapy 
177Lu 6.71 d b-  (498 keV), g (113, 208 keV) Therapy 
 
Table 2. Radioactive properties of selected radiolanthanide isotopes. Data is drawn 
from reference [4]. Those entries in bold are in clinical use. 
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Readers should exercise caution when digesting the literature in this subject area as 
the nuclear data characteristics cited can sometimes be inconsistent. The data in 
Table 2 has been drawn largely from reference5a and corroborated by referring to 
nuclear data sheets at the National Nuclear Data Center, Brookhaven National 
Laboratory.5b  
 A number of radiolanthanides are well known and are now widely investigated 
for a variety of applications (see later sections). In the following section, we wish to 
highlight some relevant isotopes that are in the infancy of their development. The 
radiosynthesis of these radiolanthanides is often complex and expensive, and whilst 
we have alluded to some of the radiosynthesis procedures below, a general discussion 
is beyond the scope of this article. 
 
134Ce/134La 
Despite reports of the Auger electron and positron emitting 134Ce/134La isotopes6 (half-
lives: 3.16 d, 6.45 min) there are no reports of the development of the use of this PET 
isotope in preclinical experiments. While the coordination chemistry of these early 
lanthanides is slightly varied from the later lanthanides,7 134Ce/134La could find similar 
utility as other more familiar lanthanide isotopes. 134Ce was produced from a natural 
abundance lanthanum metal disc bombarded with 70-72 MeV protons. The product 
was dissolved using NaBrO3 and HNO3 and extracted into methylisobutylketone. 
Significant 135Ce was produced meaning that samples were initially left for two days 
for the by-product to decay. 
 
140La 
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140La is a fission product that is a beta emitter with a half-life of 1.68 days. It decays to 
the stable 140Ce isotope. Kobayashi et. al. have reported its inclusion within a fullerene 
framework and shown the biodistribution of the agent within a rat.8 The energy of the 
beta decay is 3.76 MeV with the major gamma energy transition (g28) at 1.596 MeV 
which is intermediate to those of 90Y (2.28 MeV) and 166Ho (711 keV).  One point of 
concern may be the lower thermodynamic stability of lanthanum complexes in 
comparison to other smaller lanthanide ions. 
 
140Nd/140Pr 
Zhernosekov et al. have reported the production of 140Nd up to 200 MBq.9 The nuclear 
processes natCe(3He, xn) and 141Pr(p, 2n) were investigated and the chemical isolation 
of 140Nd(III) from Ce(III) and Pr(III) was performed by cation-exchange 
chromatography with a decontamination factor from the respective target material of 
~108 and 7×105. A 140Nd/140Pr generator system was developed utilising the DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) complex of 140Nd to isolate 
the positron emitter, 140Pr (half-life = 3.39 min). The generator showed high elution 
yield and high chemical and radiochemical stability, with the activity of the daughter 
nuclide sufficient for in vivo PET investigations. However, it was noted that the use of 
140Nd/140Pr as an in vivo radionuclide generator, needs more consideration, especially 
when one considers the use of the 140Nd DOTA complex used to generate free 140Pr. 
It was suggested that ligands other than DOTA should be utilised for this purpose.9 
 
141Ce  
141Ce has been commonly used in tracer studies. For example, in older literature the 
long half-life of 141Ce (β-, half-life = 32.5 d) made it attractive as a tracer when loaded 
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into porous di-vinyl benzene polystyrene microspheres (typically 5 – 15 μm diameter) 
as a tracer to examine blood flow and other vascular functions.10,11,12 141Ce has even 
found applications in plant ‘imaging’, being employed as a tracer in the growth of 
horseradish13 and tea plants.14 The production of 141Ce-ceria and nanoceria powders 
as potential imaging and therapeutic agents has been examined.15   
 
144Ce/144Pr generator  
144Ce is a fission product, undergoing radioactive decay with a half-life of 284.1 d via 
b
- emission to 144Pr. 144Pr has a half-life of 17.3 min and decays via b- emission to 
144Nd. The long half-life of 144Ce would appear to preclude any useful therapeutic 
applications. However, the rapid separation of these isotopes has been achieved by 
absorbing them to alumina and, under oxidizing conditions, Ce(IV) is retained while 
Pr(III) may be eluted. The process was found to be quantitative.16 	
 
149Tb,152Tb,155Tb,160Tb,161Tb 
149Tb (half-life = 4.1 h) is a dual alpha emitter (3.97 MeV, 16.7%) and PET isotope 
(730 keV, 7.1%) making it a potential a-PET radiotheranostic.17 152Tb (half-life = 17.5 
h) is a positron emitter (1.08 MeV, 17%) and 155Tb (half-life = 5.32 days) decays by 
EC (100%) and is suitable for SPECT.  161Tb (half-life = 6.9 days) is a low energy beta 
emitter (0.15 MeV) and also produces low energy photons making it suitable for 
therapy as well as SPECT.  The majority of these Tb isotopes can be made at ISOLDE 
(isotope mass separator on-line facility)/CERN18 by the radiation of a Ta-Re target and 
mass separation of the isotopes, except for 161Tb which has been synthesised by the 
neutron irradiation of 160Gd.19 
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172Hf/172Lu generator 
 
The 172Hf radionuclide (half-life = 1.8 y) decays by EC to 172Lu (half-life = 6.7 d), which 
subsequently decays to stable 172Yb. 172Lu emits gamma rays ranging from 79 to 1622 
keV. The generator has been used for analytical applications,20 but has yet to find 
applications as a therapeutic agent, and coordination complexes of 172Lu have not yet 
been reported. 
 
The separation chemistry of radiolanthanides is clearly a challenging subject area and 
Liu et al. have reported an amide-based tripodal ligand (6-[2-(2-diethylamino-2-
oxoethoxy)ethyl]-N,N,12-triethyl-11-oxo-3,9-dioxa-6,12-diazatetradecanamide), 
shown in Fig. 1, that acts as an extractant for selected radiolanthanide ions.21 Using a 
multitracer solution containing twelve radioactive rare earth nuclides (140La, 141Ce, 
147Nd, 148Pm, 147Eu, 149Gd, 153Tb, 160Er, 167Tm, 166Yb and 177Lu)	 they were able to 
demonstrate high extractability and excellent cation selectivity towards 147Pm, which 
possessed the highest extraction equilibrium constant, logKex = 10.65. The authors 
report X-ray structural data for Ln(III) complexes of this ligand with picrate (picric acid 
= 2,4,6-trinitrophenol) as co-ligand, with the coordination sphere best described as a 
monocapped distorted square prism or antiprism. However, with a modest stability, it 
is unlikely that Ln(III) complexes of this ligand could be used for some of the biological 
applications that are discussed in this review. 
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Figure 1. Tripodal ligand used for the extraction of 147Pm.  
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3. Coordination chemistry of radiolanthanides 
The coordination chemistry, physical properties, and applications of lanthanide ions 
are vast and we encourage readers to utilise the number of general reviews on 
lanthanides,22 which describe the wide breadth of ligand design, as well as a more 
focused review discussing their breadth of potential in cancer diagnosis and therapy.23 
Also of relevance, are a number of previous reviews that summarise therapeutic 
radiopharmaceuticals (which includes some coverage of 153Sm and 166Ho),24 
prospective theranostics,25 as well more specific topics such as radiopharmaceuticals 
for palliative care of patients with castration-resistant prostate cancer metastatic to 
bone, where 153Sm has particular relevance.26 While the breadth of 177Lu application 
to the development of radiopharmaceuticals has been recently documented in detail,27 
we will highlight some (topical) examples of its coordination chemistry and application. 
 Finally, it is obvious from the literature that there are inconsistencies when 
naming the many chelating ligands referred to within this review. Thus, 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid is frequently referred to as its 
synonym, DOTA, but also sometimes referred to as H4DOTA (to reflect the correct 
protonation state of the free ligand). For consistency with the majority of the literature 
reports we will adopt the use of DOTA as the abbreviation and assume this naming 
protocol for all other relevant ligands throughout this review. 
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3.1. Complexes based on (poly)aminophosphonic acids 
Radiopharmaceuticals based on (poly)aminophosphonic acids has been a primary 
area of development in the last two decades, often specifically targeting bone therapy 
and imaging. A wide range of radionuclides have been investigated with such ligand 
systems, many of which (99mTc, 68Ga, 227Th, 228Ac, 212Bi, 188Re) are beyond the realm 
of this current review, but are discussed in the context of (poly)aminophosphonic acids 
elsewhere.28 Specific review articles have also focused upon the targeted treatment 
of bone metastases using phosphonate-based ligands29 and a broad range of 
radionuclides.30 
 
3.1.1. Acyclic ligand derivatives 
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Figure 2. Examples of acyclic ligands based on aminophosphonic acids. 
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Although not an aminophosphonic acid, the structurally simplest biphosphonic acid 
derivative is pyrophosphonic acid (Fig. 2). The complexation of this ligand has been 
reported with 177Lu, where the complex was obtained using a ligand:metal ratio of 60:1. 
No precise information on the complex speciation was given and no corresponding 
work with natural Lu(III) was detailed. Preliminary animal imaging studies showed high 
skeletal uptake of 177Lu.31 
 Ethylenediaminotetramethylenephosphonic acid (EDTMP, Fig. 2) has been 
one of the most widely studied aminophosphonate based ligands. This is primarily due 
to the development of 153Sm-EDTMP (also known as samarium lexidronam, or 
Quadramet) as an intravenous treatment for cancer-induced pain which has spread to 
the bone.32 Remarkably, given the clinical importance of this compound, the first solid 
state structural characterisation (Fig. 3) of the Sm(III) complex of EDTMP was only 
recently reported using EXAFS,33  confirming the assumptions (EDTMP acts as a 6-
coordinate ligand) previously made about the solution state speciation and ligand 
binding mode to Sm(III). The thermal analyses of Ln(III) complexes of EDTMP have 
also been reported in detail.34  
  
 
 
 
 
 
  
 
Figure 3. Geometry optimized DFT structure of [Sm(EDTMP)]5−, used to fit the EXAFS 
data. Bonds to the remote N atoms, beyond 2.7 Å, are not explicitly drawn. Additional 
coordination from solvent is not explicitly modeled. Relevant Sm···X atom separations 
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are shown with the distance closest to the atom of interest (Sm−O bond lengths are 
shown in bold). Reprinted with permission from Yang et al., Mol. Pharmaceutics 2015, 
12, 4108-4114. Copyright 2015 American Chemical Society. 
 
Stability constants and dissociation rates for Sm(III) and Y(III) complexes of EDTMP 
are known:35 Sm-EDTMP with log KML = 20.71 and for Y-EDTMP with log KML = 19.19. 
Interestingly, in a modelled blood plasma medium the Sm(III) complex is present as 
the (mono-protonated) form [Sm(HEDTMP)Ca]2-. In related studies on Eu-EDTMP it 
was shown36 that the anionic carbonate complex [Eu(EDTMP)(CO3)]
7- was 
thermodynamically stable with low dissociation constants. The authors report the X-
ray crystal structure (Fig. 4) which shows an 8-coordinate complex, with the EDTMP 
acting as a 6-coordinate ligand and carbonate as a bidentate (no water is in the 
coordination sphere). It is noteworthy that these results may provide insight into the 
uptake mechanism of 153Sm-EDTMP. Work has also investigated the 152Eu and long-
lived 154Eu radio-contaminants that are present in 153Sm-EDTMP.37   
 
  
 
 
 
 
 
 
 
Figure 4. X-ray crystal structure of [Eu(EDTMP)(CO3)]
7-. Copyright © 2006, Royal 
Society of Chemistry. 
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Beyer et al. have described the influence of EDTMP levels on the biodistribution of 
141Ce, 145Sm, 149Gd, 167Tm and 225Ac.38 It was found that, for liver uptake, there was a 
strong dependence on the ionic radii of the ligand-free cation in question, with 141Ce 
and 225Ac displaying the greatest hepatic concentration, whilst the uptake of 167Tm was 
an order of magnitude less.  
 170Tm-EDTMP has been proposed as a cost-effective alternative to 89SrCl2 for 
bone pain palliation.39 170Tm has a lower beta energy than 89Sr (half-life = 50.5 d), and 
the accompanying gamma photons can be imaged using scintigraphy studies (Fig. 5). 
The complex was synthesised in the pH range of 5-8 and was characterised by paper 
chromatography and paper electrophoreses, with a corresponding radiochemical 
purity of >95%. Biodistribution studies in rats showed good bone uptake (Fig. 5) with 
low dosage to soft tissue and vital organs. 
 
 
  
 
 
 
 
 
 
 
 
Figure 5. Scintigraphic images of Wistar rats recorded after administration of 170Tm-
EDTMP at (A) 3 h, (B) 7 days, (C) 15 days and (D) 60 days. Copyright Das et al. Nucl. 
Med. Biol. 36 (2009) 561-568 (2009 Elsevier Ltd). 
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177Lu-EDTMP and 177Lu-DOTMP (Fig. 6, discussed later) have been isolated using 
177LuCl3.
40 The long-term storage radiochemical purities were found to be very good 
with the DOTMP species showing the better resilience; both compounds possess high 
in vitro stabilities. Bone uptake studies on rats showed that the EDTMP complex 
performed the best, but with higher retention in the liver and kidneys. 
 Following on from the successful application of EDTMP-based complexes, a 
large number of structurally related acyclic aminophosphonate ligands (Fig. 2) have 
been studied. A relatively rare example of 175Yb chemistry has involved the 
development of complexes with a range of these acyclic polyaminophosphonates (Fig. 
2), including EDTMP, PDTMP (propylenediaminotetramethylenephosphonic acid), 
DTPMP (diethylenetriaminopentamethylenephosphonic acid) and TTHMP 
(tetraethylenetetraaminohexamethylenephosphonic acid).41 The complexes were 
synthesised from 175YbCl3 and were analysed and purified using paper 
chromatography and paper electrophoresis. 
 The propylene bridged ligand PDTMP (Fig. 2) has also been complexed with 
153Sm.42 The complex showed good stability at pH 8.5, but less so at physiological pH 
where ~13% of radiochemical activity was lost. Biodistribution studies using rats 
showed some uptake in bone, rapid blood clearance and some uptake in liver (which 
may be due to the speciation of liberated 153Sm) and kidney.  
 3-Amino-(1-hydroxypropane-1,1-di-yl)-bisphosphonic acid (Fig. 2) is also 
known as pamidronic acid (often abbreviated to PMD), and is already used 
therapeutically (pamidronate therapy) in its own right as a treatment for osteoporosis, 
Paget’s disease, steroid-induced bone loss and certain cancers.43 Its biological half-
life is 28.7 h44 and it is an effective sequesterer of Ca2+, being able to moderate high 
Ca2+ levels in the body. Closely related ligands such as alendronic and neridronic 
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acids, are also known (Fig. 2). Early studies have shown a relatively simple synthetic 
route to these ligands and described the synthesis of the 153Sm complexes.45  The 
results of experimental hydroxyapatite binding showed that 153Sm-alendronate was 
preferred to the pamidronate and neridronate variants, perhaps due to the interactions 
of the chain group. From a synthetic perspective recent reports have also shown how 
to generate the phosphonic esters of these three ligand derivatives.46 
 The 166Ho complex of pamidronic acid has been suggested for bone pain 
palliation therapy,47 wherein good bone uptake was noted after 48 h, although at a 
level that was not superior to 166Ho-EDTMP. Interestingly, the solid-state X-ray 
structural properties of Ln(III) complexes (Ln = Eu, Tb, Sm, Nd) of pamidronate were 
only recently reported48 and show 3D open frameworks, which are presumably unlikely 
to be representative of the solution state speciation relevant to the radiolanthanide 
work. A recent DFT study also proposed that the pamidronate is likely to act as a 
tridentate ligand to Sm(III).49 The precise speciation and thermodynamic properties of 
Ln(III) pamidronate (or related) complexes in aqueous solution has not been reported. 
 Zoledronic acid ((1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid) 
is a biphosphonic acid (Fig. 2) which is closely related to the pamidronate-like ligands 
described above. It also has a high affinity for bone and is a known inhibitor of 
osteoclastic bone resorption. It is chemically robust under physiological conditions, is 
not biotransformed in vivo, and is a well-established therapeutic in its own right.50 
Zoledronic acid has been radiolabelled with a number of radionuclides including 99mTc 
for bone imaging51 and 14C in research studies into drug binding.52 More recently, the 
177Lu complex of zoledronic acid has been isolated in good radiochemical yield and 
shown good stability in the presence to human serum albumin, although the precise 
speciation has not been determined. The complex showed good bone uptake in rat 
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studies, but was not superior to the performance of 177Lu-EDTMP.53 Interestingly, the 
combined use of zoledronic acid and 153Sm-EDTMP has been investigated in 
hormone-refractory prostate cancer patients with bone metastases.54 In terms of the 
Ln(III) coordination chemistry, there do not appear to be any specific reports on the 
structural properties of zoledronate complexes. 
 The related tetraphosphonate derivative APDDMP (dimethylenephosphonate-
1-hydroxy-4-aminopropylidenediphosphonate, Fig. 2) can be conveniently 
synthesised from pamidronic acid. Both 166Ho and 153Sm complexes of the bone-
seeking ligand APDDMP have been isolated and assessed for stability and 
biodistribution in baboon animal studies.55 The studies show that 166Ho-APDDMP has 
little liver or bone uptake, but that 153Sm-APDDMP does have moderate bone uptake. 
A key observation from this work is the strong affinity of APDDMP for Ca(II), which can 
then liberate Ln(III). Interestingly, the modelled speciation for the Ho(III) and Sm(III) 
species is very different, despite a very small difference in the formation constants of 
the predominant ML(OH) species (logKML ~ 18-19), and this apparently manifests in 
very different in vivo speciation. The results for 153Sm-APDDMP point to inferior 
performance compared to 153Sm-EDTMP. 
 
3.1.2. Macrocyclic ligand derivatives 
The biomedical applications of macrocyclic ligands are well established and have 
been summarised elsewhere.56 For readers interested in the direct comparison of 
tetraazamacrocycles bearing methylphosphinic and methylphosphonic acid arms with 
their aminocarboxylate (i.e. acetate) analogues, we highly recommend the review by 
Lukes et al.57 Within that overview, the assessment of stability constant data 
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suggested that for the Gd(III) complexes of a given macrocycle framework, the logKML 
values vary according to phosphonic > acetate > phosphinic derivatives. 
 
 
 
Figure 6. Examples of macrocyclic ligands based on aminophosphonic acids. 
 
NN
NN
P
OH
P
HO
P
HO
O
O
O
P
O
OH
HO
OH
OH
HO
DOTMP or DOTP
NN
NN
OH
HO
HO
O
O
O
O
H
N P
P
O
O
OH
OH
OH
OH
BPAMD / DOTAM
NN
NN
OH
HO
HO
O
O
O
P
O
P
P
O
O
OH
OH
OH
OH
DO3ABP
OH
NN
NN
OH
HO
HO
O
O
O
O
H
N
BPAPD
P
P
O
O
OH
OH
OH
OH
NN
NN
OH
HO
O
O
O
H
N P
P
O
O
OH
OH
OH
OH
DOTA(MBP)2
O
N
H
P
P
O
O
HO
HO
HO
HO
NN
NN
OH
HO
HO
O
O
O
P
OH
O
DO3AP
OH
NN
NN
OH
HO
P
HO
O
O
O
P
OH
O
cis-DO2A2P
OH
HO
NN
NN
P
OH
HO
P
HO
O
O
O
OH
O
trans-DO2A2P
HO
OH
NN
NN
OH
HO
HO
O
O
O
P
OH
O
DO3APPrA
CO2H NN
NN
OH
HO
HO
O
O
O
P
OH
O
NH2
DO3APABn
NN
NN
OH
HO
O
O
P
O
P
P
O
O
OH
OH
OH
OH
DO2A(PBP)2
OH
P
O
P
P
O
O
HO
HO
HO
HO
OH
NN
NN
P
OH
P
HO
O
O
P
OH
P
HO
DOTPI
CO2H
O
O CO2H
CO2H
HO2C
	 21	
 
The tetraaza macrocyclic framework cyclen has yielded a wide range of phosphonic 
acid derivatised ligands (Fig. 6). Early work by Sherry and co-workers described the 
Ln(III) coordination chemistry and characterisation of the classical tetraphosphonate 
ligand DOTMP (also known as DOTP).58 Importantly, from a biological and 
radiopharmaceutical perspective, the logKML stability constants for lanthanide ion 
complexes of DOTMP are in the range of 27.6-29.6 for La(III) to Lu(III). 
 Both DOTMP (Fig. 6) and its related cyclam cousin, CTMP (also known as 
TETP, Fig. 7), have been used as ligands for 177Lu, again with a view to future potential 
as bone pain palliation agents.59 The study showed that whilst the DOTMP was 
efficiently labelled with 177Lu the corresponding CTMP reaction was poorer yielding 
and required higher, and thus less convenient, reaction temperatures to effect 
complexation. 177Lu-DOTMP showed selective skeletal uptake, minimal organ uptake 
and rapid blood clearance in biodistribution studies in rats. 141Ce-DOTMP has been 
examined as a theranostic agent for metastatic bone tumours, which demonstrated a 
strong selectivity for bone, with excess activity being excreted renally.60 
 177Lu has also been used to radiolabel macrocyclic bisphosphonates, such as 
DOTA(MBP)2, DOTA(P
BP)2, DO3AP
BP, DO2A(PBP)2, BPAPD, and NO2AP
BP (Fig. 6) 
that target bone metastasis for cancer treatment. Binding to hydroxyapatite was 
measured in vitro and all 177Lu complexes showed exclusive accumulation in the 
skeleton of Wistar rats with very low soft-tissue accumulation.61 The bisphosphonate 
complexes of DOTA(MBP)2 DO2A(P
BP)2  showed a slightly higher bone accumulation, 
but slower blood clearance. 
 The ligand trans-DO2A2P (Fig. 6) has been synthesised and a series of 
corresponding lanthanide complexes were prepared and their properties investigated 
	 22	
in solution and solid state.62 The stabilities of the Ln(III) complexes were intermediate 
to those of DOTA and DOTP. Of particular interest was the Ce(III) complex, which was 
more kinetically inert than the analogous Eu(III), Gd(III) or Yb(III) complexes. It was 
noted that increasing the number of phosphonate donors increased the kinetic 
inertness of the Ce(III) complex, while conversely, increasing the number of 
carboxylate donors increased the thermodynamic stability of the Eu(III) complex. In 
the solid state, ennea-coordinate complexes were observed for Ce(III), Nd(III), Sm(III) 
while eight coordinate complexes were observed for Eu(III), Tb(III), Dy(III), Er(III), and 
Yb(III). The radiolabeling of this ligand has also been reported: 153Sm and 166Ho 
complexes of trans-DO2A2P have been prepared (70 °C, pH 8−9).63 These complexes 
were stable in physiological solutions for up to 48 h, and show low plasmatic protein 
binding and some in vitro hydroxyapatite adsorption, specifically for 166Ho-trans-
DO2A2P. Both complexes are stable in vivo, have a fast tissue clearance with a rapid 
excretion from the whole animal body. Bone uptake was greater than for analogous 
DOTA complexes, but less than half that observed in related DOTP complexes.64 The 
accumulated radioactivity rapidly decreased with time. 
 The ligand pair of geometric isomers cis-DO2A2P and trans-DO2A2P (Fig. 6) 
have been studied with respect to their comparative biological behaviour.65 Both 
isomers were radiolabelled with 177Lu, for potential applications such as radiotherapy 
and/or imaging of bone diseases. Biological assays, such as hydroxyapatite binding, 
in vitro stability, and in vivo distribution, showed the pair had almost identical biological 
properties. 
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Figure 7. 13- and 14-membered macrocyclic ligands based on aminophosphonic 
acids. 
 
An assessment of both the 153Sm and 166Ho complexes of 13- and 14-membered 
azamacrocyclic ligands with phosphonate pendant arms (Fig. 7) has been reported.66 
The study also included the ligands DOTP, TRITP and TETP (as well as closely 
related aminocarboxylate derivatives). High radiolabelling efficiencies (>98%) were 
reported for each ligand and it was noted that the 153Sm/166Ho-TRITP complexes 
bound to hydroxyapatite, which manifested in good bone uptake in corresponding 
biodistribution studies.67 
 In an unrelated study, 160Tb has been used for the physical study of the 
adsorption of lanthanide complexes to hydroxyapatite;67 complexes of the 
phosphonate ligands DO3ABP and DOTP were studied. Adsorption was found to be 
very fast for both complexes, with the 160Tb-DO3ABP complex showing a greater affinity 
for the hydroxyapatite surface than 160Tb-DOTP, presumably due to the availability of 
the pendant bisphosphonate group.  
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 A large number of DOTA analogues have been synthesised that incorporate 
monophosphinic acid groups, primarily with a view to their Gd(III) chemistry and MRI 
applications. For example, DO3APABn was described by Hermann and co-workers.68 
Radiolabelling of DO3AP, DO3APPrA and DO3APABn (Fig. 6) have been described with 
153Sm and 166Ho.69 The study also included detailed thermodynamic studies which 
provide the stability constant data for the different Ho(III) and Sm(III) complexes in the 
series. Interestingly, the data showed logKML values ca. 24-28, revealing complexes 
of high stability. All complexes showed low human plasma protein binding and a good 
biological profile (i.e. rapid clearance from the main organs and a high rate of whole 
body excretion of radioactivity) with the phosphorus substituent imparting little 
influence upon the key physical and biological properties. 
 Another class of macrocyclic ligand that has been studied incorporates pyridine 
donors into the ring. A range of 14-membered, pyridine containing, 
tetraazamacrocycles (ac3py14, MeP2py14 and P3py14) that incorporate acetic acid or 
phosphonic acid arms have been reported (Fig. 8).70 The stability constants of the 
Sm(III) and Ho(III) complexes71 of ac3py14 are significantly lower (logKML = 
9.78/10.31) than the analogous MeP2py14 and P3py14 (logKML = 17.26/16.84 and 
18.87/19.16, respectively) complexes, and notably lower than corresponding DOTA-
type species. The 153Sm and 166Ho complexes show considerable bone uptake which 
has been ascribed to the complexes not being kinetically inert resulting in the in vivo 
metal release. This also results in significant protein binding, high liver and spleen 
uptake and slow excretion rates. 
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Figure 8. Examples of 12- and 14-membered macrocyclic ligands that incorporate 
pyridine donors. 
 
12-membered tetraaza macrocycles with integrated pyridine rings are also well known. 
Two decades ago Bornhop and co-workers pioneered the development of luminescent 
lanthanide imaging agents based on ligands such as PCTMB and P2py212 (Fig. 8). 
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The luminescent Tb(III) complexes possess high quantum yields72 and supporting 
studies reported the use of 153Sm complexes which showed localisation in bone tissue 
of rats.73 It is noteworthy that related coordination chemistry with 90Y has been 
reported with PCTMB (Fig. 8).74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Structures of TRAP ligands (based on the TACN framework). 
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reviewed.75 In particular, a class of ligand based on 1,4,7-triazacyclononane (TACN) 
are known as TRAP (1,4,7-triazacyclononane phosphinic acid) ligands (Fig. 9) and 
were originally developed by Parker and co-workers more than 20 years ago.76 The 
original design of such systems was to address the chelation of 67Ga and 111In based 
radiopharmaceuticals (Table 1) wherein the phosphinate substituents influenced the 
overall lipophilicity of the complex and thus biodistribution. After a number of years, 
interest in TRAP type ligands has increased again with the investigation of 68Ga 
complexes that show good affinity for bone. Indicative stability constants for Ga(III) 
complexes of these ligands are in the region of logKML = 21-29. Comparison with Y(III) 
(logKML ~ 10), La(III) (logKML ~7-11) and Gd(III) (logKML = 8-14) complexes shows that 
these ligands result in significantly lower logKML values for the lanthanide series. 
Unfortunately, these lower stability constants for Ln(III) complexes would seem to 
preclude their biological and/or clinical application. 
   
 
 
 
 
 
 
 
Figure 10. Dipicolinate functionalised TACN ligands for the stabilisation of Ln(III) 
complexes. 
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However, more recent progress has shown that stable Ln(III) complexes can be 
achieved through functionalisation of the TACN framework with dipicolinate arms (Fig. 
10).77 Such ligands have already been applied to optical biological imaging 
(fluorescence microscopy) using Sm(III)78 and other emissive Ln(III) ions, and 
therefore clearly represent an interesting option for radiolanthanides through the ease 
of functionalisation of the peripheral dipicolinate arms.  Mazzanti and co-workers have 
also synthesised a range of picolinate-substituted TACN ligands for Gd(III) and the 
stability constants of these species range from logKML 13.9-19.5.
79 Of course the 
radiological robustness of such systems would need to be evaluated.  
 
3.2. Complexes based on (poly)aminocarboxylic acids 
EDTA, DTPA and DOTA are the quintessential polyaminocarboxylate ligand 
frameworks, and their corresponding coordination chemistries have been studied in 
great detail over a number of decades. In a biological, pharmaceutical and bioimaging 
context, Ln(III) complexes of DTPA and DOTA (and their derivatives) continue to 
attract attention. In particular, the applications of DOTA80 and peptide-conjugated 
DOTA81 derivatives are prevalent. 
 The 144Ce/144Pr system has found application as a radiotracer in nutritional 
science more than 30 years ago, where the elimination of the Ln-EDTA complex in 
sheep was found to be more rapid than the corresponding 51Cr system.82 The complex 
51Cr-EDTA was excreted faster in faeces than 144Ce/144Pr when both were given 
together as a single injection into the reticulorumen. 
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Figure 11. Classical polyaminocarboxylate ligands. 
 
 
In fundamental studies, Sherry and co-workers previously reported the 
thermodynamic properties of Ln(III) complexes of common triaza and tetraaza 
macrocycles, including EDTA, NOTA, DTPA and DOTA (Fig. 11).83 Early studies on 
related DO3A and HP-DO3A (Fig. 11) have also reported the Ln(III) stability constants 
for such complexes showing that logKML values decrease according to the trend DOTA 
> HP-DO3A > DO3A.84 Table 3 summarises some key stability constant data for a 
range of relevant Ln(III) complexes based on some of these common ligand 
frameworks.  
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Table 3. Stability constant (logKML) data for selected ligands and relevant Ln(III). 
 Stability constant (log KML) 
Ligand Ce(III) Pr(III) Sm(III) Gd(III) Tb(III) Ho(III) Lu(III) 
EDTA  16.4 17.1 17.3f 17.9 18.6 19.8 
DTPA  21.1 22.3 22.3f 22.7 22.7 22.4 
NOTA 13.2 13.3f 13.8f 14.5f 15.1f 15.2f 16.0f 
DO3A 19.7   21.0e   23.0,a 
21.4b 
DO3AP   28.7c   28.5c  
DOTA 23.4 25.5 26.1 25.3e 26.2 26.1 25.5 
DOTMP  27.4d 28.1d 28.8d 28.9d 29.2d 29.6d 
PCTA 18.2   20.4  20.2  
a K. Kumar, et al. Pure & Appl. Chem. 65 (1993) 515-520; b A. Takacs, et al. Inorg. 
Chem. 53 (2014) 2858-2872; c S. Lacerda, et al. J. Label Compd. Radiopharm. 53 
(2010) 36-43; d A.D. Sherry, et al. Inorg. Chem. 35 (1996) 4604; e K. Kumar, et al. 
Inorg. Chem 32 (1993) 587-593; f W.P. Cacheris, et al. Inorg. Chem. 26 (1987) 
958-960. 
 
 
One of the key applications of polydentate aminocarboxylate ligands, such as DTPA 
and DOTA, has been in the successful development of Gd(III)-based magnetic 
resonance imaging (MRI) contrast agents, some of which were first approved for 
clinical use in the 1980s.85 Interestingly, this is a branch of research that has exploited 
153Gd and is focused upon understanding the possible brain deposition of Gd(III) 
following administration of a contrast agent.86 153Gd-labelled DTPA, DOTA and acetate 
have been studied in mice,87 as well as the biodistribution of 153Gd labelled analogues 
of FDA-approved commercial MRI contrast agents, gadopentetate (Gd-DTPA), 
	 31	
gadoterate (Gd-DOTA) and gadodiamide (a diamide derivative of DTPA).88 In related 
work, a 153Gd-labelled complex of HP-DO3A was also obtained, using 153GdCl3 as the 
source radionuclide.89  
 DO3A and DO2A are well known related ligand scaffolds that allow great 
flexibility and design potential through functionalisation at the macrocycle unit. 
Radiolabelled 153Sm species have been reported that use these chelating agents as 
core units that are functionalised with different glycoconjugates. The specific choice of 
sugar moiety attached to the 153Sm complex, via the macrocycle, resulted in different 
targeting abilities of 153Sm in vivo.90 
 Lanthanide complexes of the pyridine containing 12-membered macrocycle 
PCTA (3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic 
acid) have been studied by Sherry and co-workers who reported the stability constant 
data for a range of Ln(III) species (Table 3), which typically lie in the logKML range 18-
20.91 While these ligands appear more suited to smaller ions such as Ga(III) and In(III), 
the fast formation kinetics for the Ln(III) species appear attractive from a 
radiopharmaceutical perspective, and the chelate can be easily functionalized for 
bioconjugation.92 
   
 
 
 
 
 
 
Figure 12. An acyclic ligand suitable for chelating 177Lu. 
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More recently, Orvig and co-workers have developed a number of novel chelating 
ligand motifs for the consideration of labelling with radiolanthanides. The potentially 
octadentate H4azapa (adopting Orvig’s nomenclature), which was synthesised using 
‘click’ chemistry from the alkyne precursor, has shown that radiolabelling is possible 
with several isotopes, including 177Lu (Fig. 12).93 The related acyclic poly-chelate 
H4octapa class of ligand is discussed later. 
 
3.3. Complexes that incorporate porphyrins 
The radiolabelling of porphyrins in nuclear medicine has been reviewed elsewhere,94 
highlighting the large number of metallo-radionuclides that have been investigated in 
this context, including 99mTc, 57Co, 64Cu, 67Ga, 68Ga, 109Pd, 111In, 209Pb and 213Bi. The 
first metalloporphyrins based on lanthanides were synthesised in the 1970s95  and 
were initially investigated as shift reagents in NMR.96 However, the coordination 
chemistry of the radiolanthanides appears to be very rare, and we assume this is 
because the complexes formed with core porphyrin-type ligands do not have the 
requisite solubility and/or stability under physiologically relevant conditions. It should 
be noted that radiolabelling of porphyrins with 68Ga requires microwave mediated 
reaction conditions.97 The typical coordination mode of a Ln(III) with porphyrin 
structures is via the four nitrogen atoms of the ring (where the metal ion lies above the 
plane of the four donors); further stabilisation can be achieved by at least three 
external donors, particularly if these are tethered to the porphyrin core in some way. 
Alternatively, ‘double-decker’ or ‘triple-decker’ arrangements98 of alternating porphyrin 
/ Ln(III) can be formed to satisfy the coordinative requirements of the lanthanide.  
 
	 33	
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Tetraphenyl porphyrin (TTP) ligands for Ln(III). 
 
A rare report of a directly radiolabelled porphyrin-based chelator99 has utilised 
166Ho.100 The ligands were based around a standard tetraphenyl porphyrin (TPP, Fig. 
13) structure with subtle variations in the nature of the peripheral groups to modulate 
solubility and lipophilicity. The 140Nd complex of TPP has also been reported,101 
possesses high lipophilicity, and apparently showed good radiochemical purity after 
two days incubation in human serum. The lipophilic character of the complex led to 
biodistribution in mice into major organs such as liver, lungs and spleen, but also 
showed significant accumulation in tumours.  In both reports, the complexes are 
assumed to be in a 1:1 stoichiometry with the porphyrin ligand; no spectroscopic or 
structural data were presented to support these assumptions. 
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Figure 14. A functionalised tetraphenylporphyrin (TTP) derivative for Ln(III) 
encapsulation. 
 
Porphyrin-lanthanide complexes that display near-IR luminescent properties has been 
recently reviewed102 and therein describes some of the ligand design strategies that 
are employed to stabilise Ln(III) with porphyrin type ligands. For example, Fig. 14 
shows the ligand employed to chelate near-IR emitters Nd(III), Er(III) and Yb(III).103 It 
appears that such strategies have not been employed with radiolanthanides, but may 
provide useful options in the future design of chelators. 
 
 
 
 
 
 
 
 
 
Figure 15. A cationic tetraphenylporphyrin (TTP)-DOTA conjugate. 
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More commonly, porphyrin groups are often incorporated into complexes and used as 
targeting vectors, or, to provide dual imaging/therapeutic options for 
molecule/complex. In this context, the primary advantages in the use of porphyrins are 
their relatively low toxicity, tumour targeting capability, rapid clearance rates from the 
body, as well as their application in photodynamic therapy104 (opening opportunities 
for dual imaging / therapeutic agents). For example, two cationic porphyrin-DOTA like 
conjugates (Fig. 15) have been radiolabelled with 177Lu (via the DOTA site).105 
Biological evaluation undertaken using mice with fibrosarcoma tumours showed fast 
tumour localisation of the radiotracer, which was then rapidly cleared and attributed to 
the hydrophilic, cationic nature of the conjugated ligand.  
 
4. Radiolanthanides labelled with peptides and PRRT (peptide receptor 
radionuclide therapy) 
The synthesis of DOTA-peptide conjugates is a vast subject that is beyond the scope 
of this review and we recommend the review by Kovacs which deals with this subject 
in detail.106 Commonly, it is most convenient for DOTA or DTPA like ligands to be 
decorated with a reactive functional group, such as an isothiocyanate or an active 
ester, that allows easy attachment to biomolecules such as peptides. Below we 
highlight some recent examples that exploit the use of peptide functionalised ligands 
for radiolanthanides for imaging and therapeutic purposes. 
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Figure 16. Molecular structure of DOTATATE. 
 
DOTATATE (Fig. 16) is a peptide functionalised derivative of DOTA (also known as 
DOTATOC, DOTA-octreotate or DOTA-Tyr3-octreotate), and is a ligand that is used in 
combination with radionuclides for the treatment and diagnosis of cancer. The 68Ga 
complex is used for PET imaging, while the 177Lu complex of DOTATATE is also 
available in a small number of research medical centres in the USA and Europe.  
 A large number of studies have examined 177Lu radiolabelling of DOTATATE, 
which includes the effective targeting of radiotherapy in human somatostatin receptor 
subtype 2 expressed tumours.107 More recently, the comparative biodistributions and 
dosimetry profiles of 177Lu-DOTATATE and 177Lu-DOTA-anti-bcl-2-PNA-Ty3-
octreotate have been reported showing that a more favourable tumour absorbed dose 
is possible with the PNA peptide variant.108 Research into the use of 177Lu-DOTATATE 
has also included investigating radionuclide therapy in advanced bronchial 
carcinoids.109 
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 Amongst the other radiolanthanides, Zhernosekov19 has reported the synthesis 
and purification of 161Tb-DOTATATE with the 161Tb obtained from isotopically enriched 
160Gd. The synthesis of 161Tb-DOTATATE was reported using a 1:12 metal:ligand ratio 
with >99% yield at pH 4.5-5 (100°C, 0.5 h); in comparison, 177Lu may be more 
efficiently used at a 1:4 ratio. In plasma, the 161Tb-DOTATATE complex showed the 
same stability as the 177Lu analogue. Also reported, is the use of 155Tb in the formation 
of complexes of DOTATATE. SPECT imaging was utilised for preclinical evaluation.110  
 
 
 
 
 
 
 
 
Figure 17. Molecular structure of DOTANOC. 
 
DOTANOC (Fig. 17) is a DOTA peptide conjugate of the somatostatin analogue 1-
NaI3-octreotide (NOC). NOC has a high affinity for somastatin receptor types 2, 3 and 
5, which are known to be prevalent on neuroendocrine tumours and their metastases 
(normal tissue shows a low level of receptor coverage). Whilst the 68Ga complex of 
DOTANOC is routinely used for PET imaging of neuroendocrine tumours, a number 
of radiolanthanides have also been investigated. 177Lu-DOTANOC is the most widely 
studied, including patient studies111 and a detailed overview of this agent is available 
elsewhere.24 
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 Much more recently, 152Tb has been complexed with DOTANOC and directly 
employed for PET scans on AR42J tumour-bearing mice.112 152Tb was produced by 
proton-induced spallation of tantalum targets, with separation using cation exchange 
chromatography. Biodistribution studies (Fig. 18) revealed that injection of the 
radiotracer using small amounts of peptide resulted in the best tumour-to-kidney ratio. 
In other studies, the DOTANOC complex of 149Tb113 has been reported and its 
properties evaluated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. PET/CT image shown as maximal intensity projection of an AR42J tumor-
bearing mouse 2 h after injection of 152Tb-DOTANOC (3.4 MBq; 0.34 nmol 
DOTANOC). Copyright Müller et al. EJNMMI Research 6 (2016) 35. © 2017 BioMed 
Central Ltd. 
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Gastrin-releasing peptide receptors are overexpressed in a number of human cancers 
and can be targeted using bombesin derivatives of radiopharmaceuticals. The 
bombesin antagonist peptide sequence (Gln-Trp-Ala-Val-N-methyl-Gly-His-Statine-
Leu-NH2) can be conjugated with a DOTA chelate to give DOTA-sBBNA (Fig. 19) 
which has been radiolabelled with 177Lu.114 Resultant biodistribution studies showed 
high accumulation and retention within tumours and an agent that was rapidly cleared 
from the blood pool. Earlier work had already reported 149Pm with DOTA bombesin 
analogues and showed very similar in vivo characteristics to the related 153Sm and 
177Lu complexes.115    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Molecular structures of DOTA-sBBNA (top) and a folate-conjugated DOTA 
chelate (bottom). 
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More recently, Muller and van der Meulen reported the use of a DOTA chelate in the 
preparation of radioactive Tb(III) conjugates.116 They utilised 149Tb, 152Tb and 155Tb 
isotopes from the ISOLODE facility at CERN,117 as well as 161Tb through neutron 
irradiation of 160Gd. Folate DOTA conjugates (Fig. 19) of all isotopes were prepared, 
with the metal being coordinated to a DOTA-like core; the folate is attached via a 
triazole unit and an amide linkage to a DOTA carboxylate group. 161Tb complexes 
were prepared by standard procedures with the combination of ligand and metal (95˚C, 
pH 4.5). However, complexes of the other isotopes were formed directly in the 
chromatography elution in an effort to minimize loss of activity. The work demonstrated 
the potential of α and β therapy by 149Tb and 161Tb, as well as the PET and SPECT 
imaging capability of 152Tb, 155Tb and 161Tb. It was proposed that this quartet of 
isotopes offers potential users chemically/biologically identical species for multiple 
applications. 
 The melanin-binding decapeptide 4B4 has also been attached to a DO3A 
chelate and radiolabeled with 177Lu, 166Ho and 153Sm.118 Stability tests in serum and 
hydroxyapatite assays showed that the 177Lu complex was most stable. However, in 
vivo the 177Lu complex did not display the desired tumour uptake, but rather localized 
in kidneys.  
 
5. Complexes for radioimmunotherapy applications 
The development of ligand-antibody conjugates for radiolabelling is well known,119 and 
a modern detailed protocol based on the bacterial siderophore Deferoxamine 
(desferrioxamine) for the conjugation of 89Zr to antibodies via a diisothiocyanate 
phenylene linker has been described.120 It is important to note that both the antibody 
pharmacokinetic (tp) and tracer radioactive half-lives (tr) must be taken into 
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consideration when choosing a tracer isotope. The effective half-life (te) is given by 
1/te = 1/tr + 1/tp and for those antibodies with long pharmacokinetic half-lives, long lived 
isotopes with comparable decay parameters should be considered.  
 Again, the DTPA and DOTA frameworks have been some of the most popular 
chelators of choice when considering conjugation with biological molecules/vectors. 
Typically, ligands are adorned with a reactive functional group, such as an 
isothiocyanate, that allows facile attachment to biomolecules such as monoclonal 
antibodies.76 Examples of this approach have mainly focused on using 90Y and 177Lu 
radiolabelled bioconjugates, and is covered elsewhere in the literature. Below we 
highlight some recent examples, as well as detailing other radiolanthanides that have 
been used in this context. 
 
 
 
 
 
 
 
 
 
 
Figure 20. Molecular structures of CHX-A’’-DTPA and MX-DTPA. 
 
The DTPA derivative CHX-A’’-DTPA (Fig. 20) is a common choice for bioconjugation 
and recent studies have examined its conjugation with bevacizumab, a humanised 
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monoclonal antibody to target vascular endothelial growth factor (VEGF) which is 
secreted by stromal or cancer cells.121 Radiolabelling with 177Lu has been reported for 
this conjugate and in vitro cell binding studies showed good uptake by VEGF 
expressing tumour cells. The closely related bifunctional chelate MX-DTPA (Fig. 20) 
was also an early choice of ligand for labelling the monoclonal antibody K-1-21 with 
153Sm.122  
 Rituximab (anti-CD20) is a specific chimeric monoclonal antibody directed 
against CD20 surface antigens on B lymphocytes and is used to treat CD-20 positive 
Non-Hodgkin’s Lymphomas.123 Its combination with radionuclides is well known, with 
two FDA-approved radiopharmaceuticals. While the 90Y (trademarked as Zevalin) is 
well known, the 177Lu analogue is less understood and the first report of a 177Lu-DOTA 
conjugate of rituximab dates from 2009.124 A more rapid and reliable radiolabelling 
method with 177Lu has been subsequently reported.125 DTPA conjugates with 
rituximab are also well known and have been radiolabelled with a range of 
radionuclides including 99mTc126 and 67Ga.127 Research on the 177Lu-CHX-A’’-DTPA-
rituximab is well developed and animal studies have shown promising tumour uptake 
and targeting.128 153Sm-DTPA-rituximab has also been reported and was used to 
obtain SPECT images on rats129 and Beyer et al. have described the synthesis and 
use of 149Tb-CHX-A”-DTPA complexes in the formation of conjugates with the antibody 
rituximab.130  
 Thompson et al. have recently examined the CHX-A”-DTPA conjugates of the 
melanoma targeting 6D2 antibody in an attempt to correlate isotope half-lives and 
efficacy for the high energy β-emission of 166Ho and 90Y.131  The study concluded that 
the longer lived 90Y system was toxic in the murine model used and that the 166Ho 
system was more effective as a result of a match between the serum half-life of the 
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antibody and the physical (decay) half-life of the radiolanthanide. In much more recent 
studies, the 177Lu complexes of CHX-A”-DTPA have been compared with either 
conjugated rituximab or huRFB4 (a novel humanised anti-CD22 monoclonal antibody). 
The resultant studies revealed that tumour growth inhibition was improved with the 
huRFB4 derivative and further enhanced when combined with unlabelled rituximab.132   
 
 
 
 
 
 
 
Figure 21. Molecular structure of a thiol functionalised DO3A ligand. 
 
More recently, a thiol functionalised DO3A-type ligand (Fig. 21) has been reported for 
the coordination of 153Sm and 166Ho with an aim of further bioconjugation via the thiol 
terminus.133 The resultant Ln(III) complexes possessed logKML of 21.0-22.0, and 
spectroscopic studies showed that the pendant thiol does not coordinate to the Ln(III), 
even in its deprotonated form. In physiologically modelled medium the 166Ho did not 
demonstrate sufficient stability, and only the 153Sm complex was assessed for in vivo 
biodistribution studies. 
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Figure 22. Molecular structures of CC49 conjugates of DOTA-like chelates. 
 
Lewis and co-workers have prepared complex conjugates of various radiolanthanides, 
including 149Pm, 166Ho and 177Lu (from the University of Missouri Research Reactor), 
with the CC49 monocolonal antibody as potential agents in radioimmunotherapy.134 
The CC49 antibody reacts with the tumour-associated glycoprotein-72 (TAG-72) 
expressed in 85% of human adenocarcinomas (e.g. colon, breast, pancreatic, ovarian, 
prostrate, non-small cell lung and gastric). Two closely related ligand systems were 
utilised, namely DOTA-CC49 and MeO-DOTA-CC49 (Fig. 22) where the active ester 
of DOTA was coupled to the antibody to give DOTA-CC49, while an isothiocyanate 
containing DOTA ligand was coupled to CC49 to give MeO-DOTA-CC49. 149Pm has 
a half-life (53.1 h) intermediate to 166Ho (26.9 h) and 177Lu (159.6 h) and yields a DOTA 
complex with a slightly lower stability constant (logKML = 22.9 vs 26.1 (Ho) and 25.5 
(Lu)), though this is unlikely to cause significant differences in their application. In vivo 
stability was estimated via a hydroxyapatite model135 and suggested >92% stability for 
168h @ 37°C for all three complexes, although in vivo studies showed less than 5% 
uptake by the bones. Results showed that the MeO-DOTA-CC49 variant offered 
superior conjugate stability with 177Lu, while in in vitro serum studies the 177Lu were 
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more stable than 149Pm and 166Ho. In vivo studies revealed MeO-DOTA-CC49 gave 
maximal uptake for 149Pm at two half-lives, for 166Ho at four half-lives and one half-life 
for 177Lu, and thus it was found that the therapeutic efficacies were of the order 
177Lu>149Pm>166Ho. Lewis et al. extended this work to compare these pre-assembled 
reagents to a pre-targeting approach of first administering Ln-DOTA-biotin, followed 
by the later injection of a CC-49-streptavidin fusion protein. Further studies identified 
the 177Lu species as the most promising for future evaluation in toxicity and multiple 
dose therapy studies.136 
 Other DOTA conjugated systems include those that have been functionalised 
with the non-peptide vitronectin receptor antagonist TA138.137 Radiolabelling with 
177Lu was best achieved using anaerobic formulation conditions that minimised 
radiolytic degradation of the conjugate. The 177Lu radiolabelled form of the murine 
7E11 monoclonal antibody has also been reported, using DOTA as the chelator, as a 
targeted prostate-specific agent.138 
 155Tb complexes of DOTA-MD (minigastrin analogue: peptide sequence, H-
Leu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH), chCE7 (a glycosylated 
monoclonal anti-L1-CAM antibody) and cm09 (albumin binding entity) derivatives have 
been evaluated for SPECT imaging in tumour-bearing mice. The chCE7 sequence 
was conjugated with CHX-A”-DTPA, but no details were given of the method of 
conjugation for the minigastrin in the 155Tb-DOTA-MD complex. The long physical half-
life of 155Tb was found to be a good match to the long biological half-lives of the 
complexes. The corresponding 177Lu-DOTA-chCE7139 and 177Lu-DOTA-cm09140 
species are also known, the latter being the first folic acid targeted radiolanthanide. 
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Figure 23. Molecular structures of conjugatable NETA ligands. 
 
 
Bifunctional NETA (Fig. 23) derivatives (3p-C-NETA),141 that are closely related to the 
parent NOTA chelate, can be synthesised using a convenient ring opening of an 
aziridinium ion and have been shown to form stable 177Lu complexes via radiolabelling 
under physiologically compatible conditions.142 The complex showed good in vitro 
stability in serum and is postulated as an alternative to DOTA and DTPA derivatives. 
Further work has described the high yielding synthesis of the isothiocyanate analogue 
(3p-C-NETA-NCS) which allows facile coupling to trastuzumab (a tumour targeting 
antibody). 177Lu-3p-C-NETA-trastuzumab was evaluated in vivo and demonstrated a 
high tumour-to-blood ratio.143 
 Nimotuzumab (h-R3) is a humanised monoclonal antibody and can be 
conjugated with chelates for radiopharmacueticals. It binds to the epidermal growth 
factor receptor, which is often overexpressed in cancer cells. In studies on conjugated 
chelates DTPA and DOTA it was shown, not unsurprisingly, that 177Lu-DTPA-h-R3 
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displayed poorer in vivo stability when compared to the DOTA analogue, which also 
demonstrated good tumour specificity and uptake.144  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Molecular structures of Orvig’s acyclic octapa-type ligands. 
 
Orvig and co-workers recently developed a new class of acyclic chelate (Fig. 24) 
system (H4octapa) that can be conjugated to the HER2/neu-targeting antibody 
trastuzumab. One of the octapa systems studied was labelled with 177Lu; 
potentiometric titrations showed that the Lu(III) complex of H4octapa possessed a log 
KML of ~20, whilst NMR studies showed little fluxional conformational behaviour at 
ambient temperatures.145 The octapa chelates show some radiolabelling advantages 
over analogous DOTA conjugates, as well as improved in vivo biodistribution profiles 
and SPECT imaging results when compared to the 177Lu-DOTA-trastuzumab. The 
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same group has expanded the octapa ligand motif to include a propyl (rather than 
ethyl) backbone (H4C3octapa, Fig. 24), which resulted in a reduced stability constant 
for the Lu(III) complex and poorer serum stability for the 177Lu analogue.146 
  
6. Radiolanthanides linked to, or incorporated into, nanostructures and 
nanoparticles 
Radiolabelled nanoparticles or nanomaterials have emerged as a very promising 
approach for diagnostic applications.147 Although a wide range of nanoparticle 
platforms are potentially available for the design of radiolabelled agents, we highlight 
some examples below that show that demonstrate the breadth of approach with 
radiolanthanides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Disulfide functionalised DOTA type ligands for the surface functionalisation 
of gold nanoparticles (GNPs). 
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177Lu labelled gold nanoparticles (GNPs) have been developed by covalently linking 
DOTA-type chelates (Fig. 25) to the surface of GNPs, which have been additionally 
PEG-ylated for improved solubility.148 Such systems have been investigated as 
‘radiation nanomedicines’ in the context of EGFR-positive breast cancer, and as 
injectable brachytherapy for neoadjuvant treatment of locally advanced breast 
cancer.149  
 PEG-labelled GNPs (represented in cartoon form in Fig. 26) have been labelled 
by 177Lu-DOTA-type complexes to allow a study into the stability, elimination and 
biodistribution of such conjugates as a function of the nature of the thiol attachment 
(mono-, di- and multi-thiol attachment at the GNP surface). Studies on athymic mice 
showed that the multi-thiol attachment at GNP gave the greatest stability in vivo and 
the lowest liver uptake of 177Lu and it is this system that is proposed as a radiation 
treatment for breast cancer.150 
 
 
 
 
 
 
 
 
 
Figure 26. Cartoon representation of a GNP co-functionalised with a radiolanthanide 
chelate and a targeting vector (such as an antibody). 
 
Shanehsazzadeh et al. have described the conjugation of DTPA to a 
superparamagnetic iron oxide nanoparticle (SPION).151 The complexation of a 
GNP
Radiolanthanide
Targeting vector
PEG linker
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radiolanthanide to these ligands will yield potential dual mode imaging agents 
(SPIONs are known as T2 MRI contrast agents). Using commercially obtained 
SPIONs, with an amino functionalised dextran stabiliser coating, DTPA bis-anhydride 
was reacted with the terminal amine to give a surface-attached pendant DTPA-
monoamide ligand. The implied ratio was two ligands to each SPION, though no data 
was advanced to show this was the case. The ligand was complexed with 177Lu (90 
MBq), though the amount of SPION used to complex the ion was not reported. 
Magnetic separation was used to conveniently isolate the complex (and un-complexed 
SPION) and chromatography was used to determine the ratio of complex to free Lu(III) 
ion. It seems probable that a vast excess of SPION-DTPA was used, meaning that the 
isolated 177Lu(III) species is largely un-complexed ligand that is not readily separated 
from the complex.  In vivo studies suggest that the SPION causes fast clearance of 
the agent from most tissue, with a significant loading in the reticuloendothelial system 
(liver and spleen). 
 177Lu-DOTATATE complexes have been encapsulated within PEG-coated 
PLGA (polylactic-co-glycolic acid) nanospheres,152 which are a form of biodegradable 
polymer successfully developed for biomedical applications.153 177Lu-DOTATATE was 
incubated in the presence of the PLGA nanoparticles to give encapsulation efficiencies 
of 58-77% based on the activity of the resultant supernatant. The relatively large (ca. 
300 nm) spherical particles were co-functionalised with anti-b-hCG antibodies with the 
aim of enhancing tumour targeting and reducing radiation damage to the kidneys of 
Wistar rats.154  
 EDTMP-doped hydroxyapatite nanoparticles have been reported as a possible 
means of a new carrier system for radiotherapy.155 The hydroxyapatite was formulated 
in the presence of the EDTMP, which then provides the potential chelation site for the 
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lanthanide although, to the best of our knowledge, the 153Sm has not yet been 
reported. In related work, EDTMP-capped NaLuF4:Yb,Tm,
153Sm upconverting 
nanoparticles have been proposed as blood pool imaging agents.156 The nanoparticles 
show good adhesion to red blood cells and no toxicity at a dose of 100mg/kg in mice. 
These systems couple useful luminescence properties with SPECT imaging capability 
(Fig. 27). 
 Ho(III) has been used as the lanthanide component in the synthesis of iron 
garnet, which was then spun into polyacrylonitrile bandages.157 The bandages were 
then neutron activated to give 166Ho containing bandages. These nanocomposites of 
166Ho have been proposed as a feasible avenue for the treatment of skin cancer. 
 177Lu labelled cerasome particles, that also encapsulates indocyanine green (a 
FDA approved near-IR fluorescent agent for clinical applications), can be developed 
from sol gel and self-assembly processes. The 177Lu chelate was a PEG-linked 
distearoyl terminated DOTA species, and the resultant cerasome was postulated as a 
dual imaging and phototherapeutic platform for cancer cells.158 
 In a separate study, Simonelli et al. examined the cytotoxicity of 141Ce-CeO2 
nanoparticles on mouse fibroblast Balb/3T3 cells.159 Multifunctional particles based on 
radiolabeled (141Ce, 111In and 65Zn) cerium oxide particles have also been described 
and applied to in vivo imaging of nude mice. The surface coating of the CeO2 can be 
modified to modulate the physiological and pharmacokinetic properties of 
nanoparticles.160 
 Another approach to the development of radiolabelled particles has 
investigated the use of 177Lu loaded core-crosslinked polymeric micelles that can be 
prepared with a DTPA-type chelator.161 This species was investigated in a 
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combination therapy approach with cyclopamine-loaded liquid-lipid particles in both 
breast and pancreatic cancer models. 
  
 
 
Figure 27. SPECT/CT imaging in vivo of mouse after intravenous injection of EDTMP-
coated nanoparticle:153Sm at different time points and different sections. The upper 
line: (a–b) 3D reconstruction at the different angles of rotation and (c) their coronal 
plane and (d) sagittal plane of mouse with injection of EDTMP-coated 
nanoparticle:153Sm at 0.5 h. The lower line: (e–f) 3D reconstruction of mouse at the 
different angles of rotation, and (g) their coronal plane and (h) sagittal plane with 
injection of EDTMP-coated nanoparticle:153Sm at 1 h. (Ar: Artery, He: Heart, Li: Liver, 
Sp: Spleen). Copyright Peng et al. Biomaterials 34 (2013) 9535-9544 (2013 Elsevier 
Ltd). 
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Fe3O4 nanoparticles have been investigated for their utility to carry radiolanthanides 
for the treatment of arthritis. Radiolanthanide loading of the nanoparticles was 
achieved by replacement of surface Na+ ions with trivalent 153Sm, 166Ho, 169Er and 
177Lu.162 The materials showed good stability in vitro and retained >70% radiochemical 
purity after 48 h storage in the presence of competing DTPA. This is an interesting, 
and perhaps surprising observation given the known logKML data for Ln-DTPA 
complexes (see Table 3). 
 
 
 
 
 
 
 
 
 
Figure 28. Cartoon representation of fullerene encapsulated 177Lu. 
 
Small diameter carbon nanospheres can be co-functionalised with an integrin 
targeting peptide cRGDfK and a 177Lu labelled DOTA chelate (linked via a classical 
amide group).163 Carbon nanospheres are attractive scaffolds as they are generally 
regarded as biologically benign and relatively inert. Interestingly, it is also possible to 
incorporate 177Lu (specifically as 177LuxLu3-xN@C80) inside a fullerene cage (Fig. 
28).164 The encapsulated 177Lu(III) ions were not released for at least one half-life (6.7 
177-LuxLu3-xN@C80
surface functionalisation for 
solubility, biocompatibility and 
targeting
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days) showing the robustness of the system, and the fullerene was surface tagged 
with an interleukin-13 peptide. The mechanism for the loss of 177Lu from the cage 
beyond this timescale has not been postulated, but assumed to proceed via radiolytic 
damage. The long-term stability of related Gd(III) species (e.g. gadofullerenes) that 
have potential in MRI has already been well documented.165 
 
7. Future prospects and untapped potential 
When we consider the radioisotopes of the metallic elements, including the f block, 
the periodic table becomes very large indeed. The radiolanthanides offer rich and 
untapped opportunities for both imaging and therapeutic applications. The Ln(III) ions 
generally have similar chemistry (the only consideration being complexes of the larger 
lanthanides, early in the series, typically displaying slightly lower stability constants for 
a given ligand). Therefore, these isotopes offer the possibility of being used as a 
‘cocktail of ions’ with a suitable ligand. This implies that a, β-, β+ and g radiation may 
all be accessible, with some degree of choice on the energy and lifetime of the 
radioactive processes. More specifically, the radiolanthanides offer species emitting a 
high proportion of high energy penetrating radiation that are suitable for diagnostic 
applications (e.g. SPECT or PET), while other radiolanthanides emit non-penetrating 
particles (electrons or alpha particles), which are more suitable for therapeutic 
applications. Conveniently, some therapeutic radiolanthanides also emit penetrating 
photons which may be useful for the imaging of the therapeutic agent itself. 
Furthermore, the energy and hence range in tissue of these varying particles also 
needs careful consideration. For example, the variation in the energies of the beta 
particles between 90Y (11 mm tissue penetration), 166Ho (9 mm), 149Pm (5 mm) and 
177Lu (2 mm), will have implications with regards to the size of tumour that a 
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therapeutic reagent should be matched with. Further still, one also needs to consider 
the half-life of the isotope, which should match the half-life of the final reagent. Clearly 
a therapeutic reagent which dissipates most of its energy before it reaches its 
biological target will do more harm than good. For example, Lewis and co-workers136 
reported a comparison of 149Pm, 166Ho and 177Lu for use in CC49 radioimmunotherapy.  
With 96 h required to reach maximum tumour loading, the 26.9 h half-life of 166Ho was 
not appropriate for conventional radioimmunotherapy. However, a pre-targetting 
strategy using streptavidin-labelled CC49, followed by a clearing reagent and then a 
biotin-labelled radiocomplex, allowed maximum tumour uptake in 4 h.166 However, 
even with more favourable kinetics, the 9 mm range of 166Ho was unsuitable for a 1 g 
tumour, with less radiative energy being delivered to the xenograft compared to the 
149Pm and 177Lu analogues.  
 Although at first sight there are a large number of ligands that have been used 
to synthesise radiolanthanide complexes, closer inspection reveals a relatively narrow 
design philosophy based on (poly)aminophosphonates and (poly)aminocarboxylate 
derivatives. Clearly, several key ligand derivatives such as bone-targeting EDTMP, or 
DOTA and DTPA, are commercially available, often in functionalised form to allow 
further conjugation. As noted elsewhere, the choice of ligand should clearly be 
matched with the characteristics of the radiolanthanide. Consideration of 
thermodynamic stability should be balanced with the formation kinetics of such 
species; this is particularly important for the practicalities of the synthesis of 
radiopharmaceuticals. However, a caveat for this latter point are the advantages 
offered by the long half-lives of many of the viable radiolanthanides. 
 A frequent observation from a number of the studies described in this review is 
the lack of detail regarding the precise speciation of some of the ligand:radiolanthanide 
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species. This is particularly true of the work on acyclic aminophosphonate chelate 
derivatives where there is a paucity of information regarding speciation and stability 
constant data on non-radioactive analogues, as well as more traditional methods for 
coordination complex characterisation. We assume such issues partially explain why 
DTPA and DOTA-like chelates are so popular, as the Ln(III) coordination chemistry is 
assumed to be well defined and understood. However, there are several reports 
detailing the release of the metal ion from the DOTA framework over the course of the 
nuclear decay. An elucidation of the mechanism of this process is clearly hampered 
by the low concentrations of species involved and their hazardous nature. However, it 
is clear that a better understanding of this process may identify criteria for the design 
of new ligands and even allow the design of new materials which can positively utilise 
the released daughter ion in further down-stream applications.  
 The combination of radiolanthanides with nanoparticle and/or nanomaterial 
type structures appears to offer very rich design opportunities.  This is particularly true 
when considering the opportunities presented by multimodality167 approaches. While 
the in vivo or in vitro concentration regimes for radiolanthanide species would render 
them unsuitable for either MR or optical imaging work, supporting work on 
fluorescently labelled analogues could be a crucial tool in understanding species at 
the cellular level. Of course, the complexity of any assembly must be robust in a 
radiological sense, and it is interesting to note that there are approaches to reducing 
radiolysis.168 
 Over the next decade researchers (across the physical and biological sciences) 
and clinicians can expect rapid development in the utility and application of 
radiolanthanides. This review has highlighted some of the key classes of chelating 
agents that are currently used, but there are clearly huge opportunities in the design 
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of new targeted systems that can match the radioactive properties of the lanthanide to 
the imaging and therapeutic targets. 
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